Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) Drug Analysis 2017 - ResearchAndMarkets.com

Research and Markets
Posted on: 20 Feb 18

The "Drug analysis: Binimetinibi" drug pipelines has been added to ResearchAndMarkets.com's offering.

Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK pathway. Inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition of the production of various inflammatory cytokines including interleukin-1, -6, and tumor necrosis factor.

The author believes that because half of microsatellite instability-high (MSI-H) tumors also harbor mutations in BRAF, the combination of binimetinib, encorafenib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) , and Erbitux (cetuximab; Eli Lilly/Merck KGaA) has the potential to compete with the programmed death-1 (PD-1) inhibitors currently approved for MSI-H patients. Although this triplet combination could become an important option for colorectal cancer (CRC) patients with BRAF mutations, the author expects that safety, tolerability, and cost considerations will have to be made in order for this pipeline regimen to successfully compete within the market.

Key Topics Covered:

List of Figures

Figure 1: Binimetinib for colorectal cancer - SWOT analysis

Figure 2: Drug assessment summary for binimetinib in colorectal cancer

Figure 3: Drug assessment summary for binimetinib in colorectal cancer

Figure 4: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016-25

Figure 5: Binimetinib for melanoma - SWOT analysis

Figure 6: Drug assessment summary of binimetinib in melanoma

Figure 7: Drug assessment summary of binimetinib in melanoma

List of Tables

Table 1: Binimetinib drug profile

Table 2: Binimetinib Phase III data in colorectal cancer

Table 3: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25

Table 4: Patients treated with binimetinib in the US and five major EU markets, by country, 2016-25

Table 5: Binimetinib drug profile

Table 6: Binimetinib ongoing Phase III trials in melanoma

Table 7: Binimetinib and encorafenib combination Phase II trial data in melanoma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6l7dmz/binimetinib?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180220006322/en/

Business Wire
www.businesswire.com

Last updated on: 20/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.